Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMG3WBJ)

• Drug Name: YH012 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Aggressive cancer	2A00-2F9Z	Investigative	[1]

• Cross-matching ID: TTD Drug ID: DMG3WBJ

Molecule-Related Drug Atlas

Drug(s) Targeting Erbb2 tyrosine kinase receptor (HER2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Lapatinib	DM3BH1Y	Breast cancer	2C60-2C65	Approved	[2]
Dacomitinib	DMOH8VY	Non-small-cell lung cancer	2C25.Y	Approved	[3]
BIBW 2992	DMTKD7Q	Non-small-cell lung cancer	2C25.Y	Approved	[4]
Merimepodib	DM0HS92	Breast cancer	2C60-2C65	Approved	[5]
NERATINIB MALEATE	DMEDU7B	HER2/NEU overexpressing breast cancer	2C60-2C65	Approved	[6]
Margetuximab	DMKEY6S	HER2-positive breast cancer	2C60-2C65	Approved	[7]
Trastuzumab	DMZQOUX	Breast cancer	2C60-2C65	Approved	[8]
Tucatinib	DMBESUA	HER2-positive breast cancer	2C60-2C65	Approved	[9]
Pertuzumab	DMHJV0X	Adrenal gland neoplasm		Approved	[10]
Masoprocol	DMMVNZ0	Prostate cancer	2C82.0	Approved	[11]

Drug(s) Targeting Tumor associated calcium signal transducer 2 (TACSTD2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Sacituzumab govitecan	DMUWFD8	Breast cancer	2C60-2C65	Approved	[12]
SKB264	DMSTEFK	Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[13]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Erbb2 tyrosine kinase receptor (HER2)	TT6EO5L	ERBB2_HUMAN	Not Available	[1]
Tumor associated calcium signal transducer 2 (TACSTD2)	TTP2HE5	TACD2_HUMAN	Not Available	[1]

References

• [1] Clinical pipeline report, company report or official report of Biocytogen
• [2] Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7.
• [3] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7422).
• [4] Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
• [5] Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
• [6] 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
• [7] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [8] Her2/neu is not a commonly expressed therapeutic target in melanoma -- a large cohort tissue microarray study. Melanoma Res. 2004 Jun;14(3):207-10.
• [9] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
• [10] Clinical pipeline report, company report or official report of Roche (2009).
• [11] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
• [12] Sacituzumab Govitecan: First Approval. Drugs. 2020 Jul;80(10):1019-1025.
• [13] ClinicalTrials.gov (NCT04152499) Phase I-II, FIH, TROP2 ADC, Advanced Unresectable/Metastatic Solid Tumors, Refractory to Standard Therapies (A264). U.S. National Institutes of Health.